Physician profile
Amer Abdulla
NPI 1437533205
$306,742.30
in general payments reported to CMS, 2019-2025
19 companies · $123 in 2025
The $123 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $600 · 2020: $186 · 2021: $305K · 2023: $308 · 2024: $264 · 2025: $123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $695.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $694.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $304,693.38 | 2021 | |
| Boston Scientific Corporation | $336.23 | 2020-2025 | Watchman Access System, Bodyguardian, Watchman Flx |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $318.00 | 2019-2024 | Lifevest |
| Astellas Pharma US INC | $223.39 | 2020-2021 | |
| Amgen INC. | $177.09 | 2019-2023 | Repatha |
| Astrazeneca Pharmaceuticals LP | $175.65 | 2019 | |
| Abbott Laboratories | $173.29 | 2019-2021 | |
| Zoll Circulation INC | $129.25 | 2021 | |
| Biotronik INC. | $119.09 | 2019 | |
| Novartis Pharmaceuticals Corporation | $117.73 | 2019-2021 | |
| Philips North America LLC | $67.99 | 2025 | Igt Devices Systems Undivided |
| E.R. Squibb & Sons, L.L.C. | $60.78 | 2021-2025 | Camzyos |
| Lantheus Medical Imaging, INC. | $49.89 | 2023 | Definity |
| Janssen Pharmaceuticals, INC | $33.03 | 2019-2021 | |
| Pfizer INC. | $30.45 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $16.24 | 2020 | |
| Chiesi USA, INC. | $12.97 | 2020 | |
| Aucta Pharmaceuticals, INC. | $7.85 | 2024 | Motpoly Xr |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amer Abdulla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.